CATX

Jonathan Robert Hunt

Known title: Chief Financial OfficerCIK: 0001375410

Jonathan Robert Hunt's purchase track record

How the stock did after each of Jonathan Robert Hunt's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
7
of 7 since June 7, 2022
Stock higher 6 months later
57%
3 months: 71%
Median 6-month return
+25.0%
3 months: +21.4%
Beat the S&P 500
57%
median +30.3% vs. index
PurchaseStockAmount3 months6 months
11/13/2025CATX$22K+142.5%+86.5%
11/25/2024CATX$49K-26.0%-35.0%
6/17/2024CATX$18K+26.9%-66.3%
5/31/2024CATX$35K+14.5%-68.5%
12/18/2023CATX$32K+273.1%+297.7%
12/1/2022CATX$33K-5.3%+39.5%
6/7/2022CATX$11K+21.4%+25.0%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 26, 2026

CATX included in pre-market movers list. Perspective Therapeutics was listed among stocks moving lower in Monday's pre-market session. The company is currently trading near its 52-week low, with an RSI of 32.3 indicating oversold conditions. Analysts maintain an average price target of $12.29, which is significantly higher than the current market price.

this person other insiders at CATX

Transaction History

CATX▲ Buy$22K
CATX▲ Buy$1K
CATX▲ Buy$114
CATX▲ Buy$9K
CATX▲ Buy$39K
CATX▲ Buy$18K
CATX▲ Buy$18K
CATX▲ Buy$17K
CATX▲ Buy$32K
CATX▲ Buy$12K
CATX▲ Buy$20K
CATX▲ Buy$7K
CATX▲ Buy$4K

We use analytics to understand how market-wall is used. No personal data is sold.